Orexo, a Sweden-based pharmaceutical company, announced yesterday its financial results for the fourth quarter of 2018.

The company reported total net revenues of SEK227.1m in the fourth quarter of 2018, up 18.9% compared to the same period in 2017.

The firm posted EBITDA of SEK42.8m in the fourth quarter of 2018, while earnings per share before dilution stood at SEK1.49, or SEK1.47 after dilution.

The company said, '2018 was a key year for Orexo. Winning the patent litigation for Zubsolv allowed us to secure the foundations for our US operations until 2032. The outlook for 2019 is encouraging; we expect profitability to continue to improve both from our US operations and on a corporate level, in line with our ambitious strategic goals to grow the business both organically and through acquisitions.'